Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes-Reference-Cited by-同舟云学术

Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes

Published:2021-06 Issue:6 Volume:57 Page:106328
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Almangour Thamer A.^ORCID,Garcia Estefany^ORCID,Zhou Qi^ORCID,Forrest Alan,Kaye Keith S.,Li Jian,Velkov Tony,Rao Gauri G.^ORCID

Funder

National Institutes of Health

National Institute of General Medical Sciences

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference70 articles.

1. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections;Falagas;Clin Infect Dis,2005

2. Colistin for lung infection: an update;Gurjar;J Intensive Care,2015

3. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society;Kalil;Clin Infect Dis,2016

4. The epidemiology of nonventilator hospital-acquired pneumonia in the United States;Giuliano;Am J Infect Control,2018

5. The 10 leading causes of death in the world, 2000 and 2012,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug–Drug Interactions in Nosocomial Infections: An Updated Review for Clinicians;Pharmaceutics;2024-08-28

2. Polymyxin B-Enriched Exogenous Lung Surfactant: Thermodynamics and Structure;Langmuir;2024-03-19

3. Tobramycin Reduces Pulmonary Toxicity of Polymyxin B via Inhibiting the Megalin-Mediated Drug Uptake in the Human Lung Epithelial Cells;Pharmaceutics;2024-03-12

4. In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment;Journal of Global Antimicrobial Resistance;2024-03

5. Ceftazidime–avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis;Infection;2023-10-25